AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 23996068
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (with and without augmentation)
Trial: 23451449
Drug: Plygersic gel
RxNorm normalized name: acetaminophen / hydrocodone bitartrate Oral Capsule [Polygesic]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plygersic gel (4% ginger and plai extract)
Trial: 23451449
Drug: 1% Diclofenac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% Diclofenac gel
Trial: 18318721
Drug: Intense Pulsed
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intense Pulsed Light (IPL) - 560-nm filter, 30 J/cm², 2.4/4.0-ms pulse with 10-ms delay, three treatments spaced 1 month apart
Trial: 18318721
Drug: Er:YAG laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Er:YAG laser - 3.8 J/cm², 30% pattern overlap, 0% interpulse overlap, 15 microm per pass, three treatments spaced 1 month apart
Trial: 10482323
Drug: Three hourly
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three hourly nebulized salbutamol
Trial: 10482323
Drug: Four hourly
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four hourly nebulized salbutamol
Trial: 1751998
Drug: Metoclopramide 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide 0.15 mg.kg‐1
Trial: 7141758
Drug: Fortimicin A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fortimicin A 2.5 mg/kg
Trial: 7141758
Drug: Fortimicin A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fortimicin A 5.0 mg/kg
Trial: 7141758
Drug: Fortimicin A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fortimicin A 7.5 mg/kg
Trial: 25256892
Drug: Whole body
RxNorm normalized name: MaxiVision Whole Body Formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole body hyperthermia treatment at 38.7-39°C for 60 minutes
Trial: 25256892
Drug: Whole body
RxNorm normalized name: MaxiVision Whole Body Formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole body hyperthermia treatment
Trial: 20093825
Drug: Renal progenitor/stem
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Renal progenitor/stem cell therapy
Trial: 18059593
Drug: Carbohydrate supplementation
RxNorm normalized name: pyrrolidone carboxylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate supplementation (1 g.kg(‐1).d(‐1))
Trial: 18059593
Drug: Glutamine supplementation
RxNorm normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glutamine supplementation (70 mg.kg(‐1).d(‐1))
Trial: 18059593
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of carbohydrate and glutamine supplementation
Trial: 10028374
Drug: New slow
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New slow release tablet formulation (Pindac) 12.5 mg every 12 h for 7 days
Trial: 10028374
Drug: Standard slow
RxNorm normalized name: Slow Sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard slow release capsule formulation 12.5 mg every 12 h for 7 days
Trial: 7672764
Drug: Liver resection
RxNorm normalized name: LIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liver resection combined with post-operative locoregional immunotherapy + chemotherapy (Group B)
Trial: 2285086
Drug: Bone-patellar tendon-bone
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bone-patellar tendon-bone augmentation
Trial: 2285086
Drug: Kennedy Ligament
RxNorm normalized name: human ligament preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kennedy Ligament Augmentation Device
Trial: 7178370
Drug: Metaclazepam (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metaclazepam (10 mg p.o. and 30 mg p.o.)
Trial: 30143879
Drug: Very thin-strut
RxNorm normalized name: Primula veris extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Very thin-strut biodegradable polymer drug-eluting stents (BP-DES)
Trial: 30143879
Drug: Thin-strut durable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thin-strut durable polymer drug-eluting stents (DP-DES)
Trial: 25899926
Drug: 1g of
RxNorm normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1g of acetaminophen twice daily for 12 weeks
Trial: 24525393
Drug: Placebo twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo twice daily for 12 weeks
Trial: 16682403
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist (0.5 mg buserelin)
Trial: 12791434
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg memantine/day
Trial: 9315417
Drug: Contraceptive vaginal
RxNorm normalized name: VCF 4% Contraceptive Vaginal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contraceptive vaginal film containing 19 mg BZK
Trial: 9315417
Drug: Contraceptive vaginal
RxNorm normalized name: VCF 4% Contraceptive Vaginal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contraceptive vaginal film containing 25 mg BZK
Trial: 9315417
Drug: VCF containing
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VCF containing 70 mg N‐9
Trial: 1586375
Drug: Preparation A
RxNorm normalized name: POVIDONE-IODINE 75 mg in 1 mL TOPICAL SOLUTION [Antiseptic Patient Preoperative Skin Preparation and Surgical Hand Scrub]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preparation A (40 mg slow-release isosorbide mononitrate)
Trial: 1586375
Drug: Preparation B
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preparation B (40 mg slow-release isosorbide mononitrate)
Trial: 1586375
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation C (40 mg slow-release isosorbide mononitrate)
Trial: 3991283
Drug: Preventive care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preventive care treatment episodes
Trial: 20543706
Drug: Antiretroviral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiretroviral therapy initiated a median of 7 weeks before delivery (cohort A)
Trial: 20543706
Drug: Zidovudine from
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zidovudine from 34 to 36 weeks gestation until delivery with single-dose nevirapine in labor (cohort B)
Trial: 15957509
Drug: Valacyclovir (3000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valacyclovir (3000 mg/day)
Trial: 2062621
Drug: HbOC vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HbOC vaccine (three doses at 2, 4, and 6 months of age)
Trial: 2062621
Drug: HbOC vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HbOC vaccine (two doses)
Trial: 2062621
Drug: HbOC vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HbOC vaccine (one dose)
Trial: 6203496
Drug: Different antidepressant
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Different antidepressant treatments
Trial: 25282871
Drug: 12-week self-administered
RxNorm normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12-week self-administered weight lifting program
Trial: 22780937
Drug: Nimotuzumab (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimotuzumab (200 mg per week for 6 weeks), palitaxel liposome 160 mg/m2, and carboplatin (AUC = 6)
Trial: 15984909
Drug: Trimetazidine 20mg
RxNorm normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimetazidine 20mg three times daily
Trial: 11776548
Drug: Oxygen-conserving nasal
RxNorm normalized name: TUBE,NASAL OXYGEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen-conserving nasal cannula (CNC) at 0.5 L/min
Trial: 11776548
Drug: Oxygen-conserving nasal
RxNorm normalized name: TUBE,NASAL OXYGEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen-conserving nasal cannula (CNC) at 1.0 L/min
Trial: 11776548
Drug: Oxygen-conserving nasal
RxNorm normalized name: TUBE,NASAL OXYGEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen-conserving nasal cannula (CNC) at 1.5 L/min
Trial: 11776548
Drug: Oxygen-conserving nasal
RxNorm normalized name: TUBE,NASAL OXYGEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen-conserving nasal cannula (CNC) at 2.0 L/min
Trial: 6839666
Drug: Control conditions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control conditions (without drugs)
Trial: 29254367
Drug: Group intervention
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group intervention program (four weekly sessions)
Trial: 28721992
Drug: Intra-pocket 20%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-pocket 20% benzocaine gel
Trial: 21423021
Drug: Genotype-informed dosing
RxNorm normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genotype-informed dosing algorithms
Trial: 21423021
Drug: Clinical dosing
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinical dosing algorithms
Trial: 16341856
Drug: LI 160
RxNorm normalized name: LIS-1
DrugBank: LIS-1 (DB18388)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LI 160 (HYF 41 mg/day)
Trial: 16341856
Drug: SJW powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SJW powder tablets 2.7 g/day (HYF 12 mg/day)
Trial: 16341856
Drug: SJW powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SJW powder tablets 2.7 g/day (HYF 0.13 mg/day)
Trial: 1090796
Drug: Topical nitrogen
RxNorm normalized name: nitrogen Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical nitrogen mustard
Trial: 6661512
Drug: Propranolol hydrochloride
RxNorm normalized name: Propranolol Hydrochloride
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propranolol hydrochloride (2 X 40 mg)
Trial: 12355570
Drug: Lidocaine preparations
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine preparations with laser assistance
Trial: 7528712
Drug: FK506 (Tacrolimus)
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: FK506 (Tacrolimus) treatment without cellular rejection
Trial: 7528712
Drug: FK506 (Tacrolimus)
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: FK506 (Tacrolimus) treatment with cellular rejection
Trial: 2168586
Drug: Calcium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplementation (1200 mg daily)
Trial: 6159865
Drug: Clomipramine hydrochloride
RxNorm normalized name: Clomipramine Hydrochloride
DrugBank: Clomipramine (DB01242)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomipramine hydrochloride treatment for 3 weeks
Trial: 30729346
Drug: Supragingival debridement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supragingival debridement (SD) with adjunctive full mouth glycine powder air polishing (FM‐GPAP) (test, n = 42)
Trial: 19375250
Drug: Valproate treatment
RxNorm normalized name: valproate
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Valproate treatment (1500 mg/day by Day 6)
Trial: 17525387
Drug: Intravenous recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous recombinant tissue plasminogen activator (rt-PA) started at 0.6 mg/kg over 30 minutes, followed by additional rt-PA via EKOS micro-infusion catheter or standard microcatheter up to a total dose of 22 mg over 2 hours.
Trial: 17525387
Drug: Combined intravenous
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined intravenous and intra-arterial approach
Trial: 2190927
Drug: 1.2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.2 mg/kg quotid. enalkiren
Trial: 2190927
Drug: 0.3 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg/kg q.i.d. enalkiren
Trial: 27828
Drug: Control (placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (placebo or no treatment not explicitly mentioned)
Trial: 30707210
Drug: Early protocolized
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early protocolized rehabilitation (consultation of physical therapy, occupational therapy, and speech and language therapy within 72 hours of ICU admission, n = 26)
Trial: 26059899
Drug: D2 supplementation
RxNorm normalized name: vitamin D2
DrugBank: Ergocalciferol (DB00153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: D2 supplementation (100 IU/kg daily)
Trial: 26059899
Drug: D3 supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D3 supplementation (100 IU/kg daily)
Trial: 26059899
Drug: Placebo (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (100 IU/kg daily)
Trial: 25317722
Drug: Oral application
RxNorm normalized name: Oral Film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral application of 5 mL CHX 0.12% solution before intubation
Trial: 21828387
Drug: 3.5% menthol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.5% menthol gel
Trial: 19903643
Drug: Scaling and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scaling and root planing (SRP) followed by low-level diode laser treatment for 5 days (Group B)
Trial: 19903643
Drug: Scaling and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scaling and root planing (SRP) followed by low-level diode laser treatment for 10 days (Group C)
Trial: 9921711
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin (aim: aPTT approximately 2 x normal)
Trial: 1984373
Drug: Thiopental 6.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiopental 6.5 mg/kg
Trial: 6412673
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg of sodium cromoglycate (SCG) aerosol
Trial: 6412673
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg of sodium cromoglycate (SCG) aerosol
Trial: 6412673
Drug: 2 or
RxNorm normalized name: CP-2 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 or 4 mg of sodium cromoglycate (SCG) aerosol
Trial: 3894841
Drug: Betahistine dimesilate
RxNorm normalized name: betahistine
DrugBank: Betahistine (DB06698)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betahistine dimesilate 36 mg daily for at least six weeks
Trial: 27739262
Drug: Carica papaya
RxNorm normalized name: Carica papaya
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carica papaya leaf extract (CPLE) administered three times daily for five days
Trial: 20530518
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose of dalteparin
Trial: 20530518
Drug: Half-dose of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half-dose of dalteparin
Trial: 16169400
Drug: L-acetylcarnitine (LAC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-acetylcarnitine (LAC) 3 g/d
Trial: 16169400
Drug: Combined L-carnitine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined L-carnitine (LC) 2 g/d and L-acetylcarnitine (LAC) 1 g/d
Trial: 10655964
Drug: Retinyl palmitate
RxNorm normalized name: Retinyl palmitate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Retinyl palmitate by inhalation (2 puffs of aerosol containing 1 mg per delivery, total 2 mg over 3 months)
Trial: 1715478
Drug: nitrendipine 10
RxNorm normalized name: nitrendipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nitrendipine 10 mg b.i.d. (n = 39)
Trial: 1715478
Drug: nitrendipine 20
RxNorm normalized name: nitrendipine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nitrendipine 20 mg o.d. (n = 39)
Trial: 1715478
Drug: nitrendipine 10
RxNorm normalized name: nitrendipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nitrendipine 10 mg b.i.d. (n = 32)
Trial: 1715478
Drug: nitrendipine 20
RxNorm normalized name: nitrendipine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nitrendipine 20 mg o.d. (n = 28)
Trial: 1715478
Drug: nitrendipine 20
RxNorm normalized name: nitrendipine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nitrendipine 20 mg o.d.
Trial: 1715478
Drug: nitrendipine 10
RxNorm normalized name: nitrendipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nitrendipine 10 mg b.i.d.
Trial: 6358177
Drug: Thienamycin formamidine/renal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thienamycin formamidine/renal dipeptidase inhibitor
Trial: 30268384
Drug: iv administration
RxNorm normalized name: IV Administration Set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iv administration of GLP-1 receptor antagonist exendin(9-39) + ischemia-reperfusion + RIC
Trial: 12148881
Drug: Prophylactic doses
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic doses of nadroparin (Fraxiparine)
Trial: 1104060
Drug: No heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No heparin prophylaxis (Control)
Trial: 1855751
Drug: Phytodolor N
RxNorm normalized name: N-6022
DrugBank: N-6022 (DB12206)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phytodolor N (3 x 30 drops daily for 3 weeks)
Trial: 27981528
Drug: 0.1 g
RxNorm normalized name: BIOTIN 0.1 g in 100 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 g Bayaspirin (ASA II group) administered at draught before sleep
Trial: 27981528
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg Adalat (control group) administered orally once a day
Trial: 27981528
Drug: 0.1 g
RxNorm normalized name: BIOTIN 0.1 g in 100 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 g Bayaspirin (ASA I group) administered at draught in the morning
Trial: 24571870
Drug: 20 ml
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 ml of 0.5% ropivacaine injected peri‐incisionally with pulmonary recruitment manoeuvre (Group 2)
Trial: 24571870
Drug: 20 ml
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 ml of 0.5% ropivacaine injected peri‐incisionally without pulmonary recruitment manoeuvre (Group 1)
Trial: 23259913
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment (daily sessions)
Trial: 23259913
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment (for compliant women)
Trial: 16109056
Drug: Eletriptan 40
RxNorm normalized name: eletriptan 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eletriptan 40 mg (mild pain intensity)
Trial: 11823892
Drug: Smoked cocaine
RxNorm normalized name: Cocaine
DrugBank: Cocaine (DB00907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smoked cocaine (0, 6, 12, or 25 mg cocaine base, depending on the session) administered during the follicular phase.
Trial: 11823892
Drug: Smoked cocaine
RxNorm normalized name: Cocaine
DrugBank: Cocaine (DB00907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smoked cocaine (0, 6, 12, or 25 mg cocaine base, depending on the session) administered during the luteal phase.
Trial: 10459958
Drug: Zidovudine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zidovudine (300 mg tablets), one tablet twice daily until the onset of labour, one tablet at onset of labour, and one tablet every 3 h until delivery
Trial: 10459958
Drug: Zidovudine (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zidovudine (300 mg tablets)
Trial: 576887
Drug: 1,500 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,500 mg/day of diethylstibestrol (DES)
Trial: 576887
Drug: 150 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg/day of diethylstibestrol (DES)
Trial: 576887
Drug: 15 mg/day
RxNorm normalized name: Climara Pro 0.045/0.015 MG/Day Weekly Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg/day of diethylstibestrol (DES)
Trial: 576887
Drug: 1.5 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg/day of diethylstibestrol (DES)
Trial: 28333536
Drug: Mom-Net intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mom-Net intervention (8-session, Internet-facilitated cognitive-behavioral treatment)
Trial: 23160726
Drug: Imeglimin (1,500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imeglimin (1,500 mg twice a day)
Trial: 23160726
Drug: Placebo added
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo added to metformin (1,500-2,000 mg/day)
Trial: 21777737
Drug: Topical treatment
RxNorm normalized name: Hongo Killer Treatment Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical treatment with CERTIFECT (fipronil, amitraz, and (S)-methoprene) applied 28 days prior to tick infestation
Trial: 21777737
Drug: Topical treatment
RxNorm normalized name: Hongo Killer Treatment Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical treatment with CERTIFECT applied 21 days prior to tick infestation